DeepMed Research

Theratechnologies, Inc.

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Public

Established: 1993-01-01

Employees: 114

Market Cap: $59.7M

Website: http://www.theratech.com

Clinical Trials

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting

Conditions: HIV Infections
Multi-Antiviral Resistance

Interventions: Biological: On ibalizumab treatment
Other: No ibalizumab or Pre-ibalizumab treatment

First Posted Date: 2022-05-24

Last Posted Date: 2025-05-21

Lead Sponsor: Theratechnologies

Target Recruit Count: 200

Registration Number: NCT05388474

Locations: 🇺🇸
Indiana University Health Inc., Bloomington, Indiana, United States
🇺🇸
Ruane Clinical Research, Los Angeles, California, United States
🇺🇸
Mills Clinical Research, Los Angeles, California, United States

and more 33 locations

The Visceral Adiposity Measurement and Observation Study

Completed

Conditions: HIV Lipodystrophy
BMI
HIV-Infections
NASH
Liver Fibrosis
Waist Circumference
Ectopic Fat
Liver Fat
Lipohypertrophy
Hepatic Fibrosis

Interventions: Diagnostic Test: Diagnostic Test
Drug: HIV Anti-retroviral Background Therapy

First Posted Date: 2022-05-20

Last Posted Date: 2023-11-18

Lead Sponsor: Theratechnologies

Target Recruit Count: 196

Registration Number: NCT05383456

Locations: 🇺🇸
Ruane Clinical Research, Los Angeles, California, United States
🇺🇸
Prism Health North Texas, Dallas, Texas, United States
🇺🇸
Fight Community Health Centers, Philadelphia, Pennsylvania, United States

and more 2 locations

TH1902 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumor
Hormone Receptor-positive Breast Cancer
Cutaneous Melanoma
Small-cell Lung Cancer
Endometrial Cancer
SORT1+ Cancers
TNBC - Triple-Negative Breast Cancer
Epithelial Ovarian Cancer
Prostate Cancer
Thyroid Cancer

Interventions: Drug: TH1902

First Posted Date: 2021-01-13

Last Posted Date: 2025-04-15

Lead Sponsor: Theratechnologies

Target Recruit Count: 70

Registration Number: NCT04706962

Locations: 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸
Pennsylvania Cancer Specialists Research Institute, Gettysburg, Pennsylvania, United States

and more 3 locations

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

Phase 1

Completed

Conditions: HIV

Interventions: Drug: Tesamorelin

First Posted Date: 2013-12-16

Last Posted Date: 2013-12-16

Lead Sponsor: Theratechnologies

Target Recruit Count: 18

Registration Number: NCT02012556

Locations: 🇨🇦
Anapharm Montreal, Montreal, Quebec, Canada

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Phase 4

Terminated

Conditions: Diabetic Retinopathy
HIV

Interventions: Drug: Placebo-Control
Drug: Tesamorelin

First Posted Date: 2012-05-04

Last Posted Date: 2018-09-11

Lead Sponsor: Theratechnologies

Target Recruit Count: 129

Registration Number: NCT01591902

Locations: 🇺🇸
Capital Medical Associates, PC, Washington, District of Columbia, United States
🇺🇸
Gary J. Richmond, M.D., PA, Fort Lauderdale, Florida, United States
🇺🇸
5P21 Rand Schrader Clinic, Los Angeles, California, United States

and more 21 locations

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

Terminated

Conditions: HIV

Interventions: Drug: Tesamorelin for injection

First Posted Date: 2012-04-18

Last Posted Date: 2018-09-11

Lead Sponsor: Theratechnologies

Target Recruit Count: 391

Registration Number: NCT01579695

Locations: 🇺🇸
Gary J. Richmond, M.D., PA, Fort Lauderdale, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States

and more 26 locations

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Placebo
Drug: Tesamorelin

First Posted Date: 2011-07-07

Last Posted Date: 2022-03-18

Lead Sponsor: Theratechnologies

Target Recruit Count: 3

Registration Number: NCT01388920

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

Phase 2

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2010-12-21

Last Posted Date: 2010-12-21

Lead Sponsor: Theratechnologies

Target Recruit Count: 55

Registration Number: NCT01264497

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Phase 3

Completed

Conditions: HIV Infections
Lipodystrophy

Interventions: Drug: Tesamorelin
Drug: Placebo for Tesamorelin

First Posted Date: 2008-02-06

Last Posted Date: 2022-09-30

Lead Sponsor: Theratechnologies

Target Recruit Count: 263

Registration Number: NCT00608023

Locations: 🇺🇸
Somero, Michael, Indio, California, United States
🇺🇸
Office of Dr. Michael Somero, Palm Springs, California, United States
🇺🇸
AIDS Research Alliance, West Hollywood, California, United States

and more 44 locations

TH9507 in Patients With HIV-Associated Lipodystrophy

Phase 3

Completed

Conditions: Lipodystrophy
HIV Infections

First Posted Date: 2005-07-22

Last Posted Date: 2013-11-27

Lead Sponsor: Theratechnologies

Target Recruit Count: 412

Registration Number: NCT00123253

Locations: 🇺🇸
Community Research Initiative of New England (CRI West), Springfield, Massachusetts, United States
🇺🇸
Bellevue Hospital Center New York University, New York, New York, United States
🇺🇸
Infectious Disease Physicians Inc., Annandale, Virginia, United States

and more 39 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy